Related Experiment Videos
[Comparison of proliferative activity in malignant lymphomas determined by immunohistologic methods with various
V Campr1, E Benesová, M Kolárová
1Hlavův I. pathologickoanatomický ústav VFN a 1. LF UK, Praha.
Ceskoslovenska Patologie
|May 1, 1997
Insights
The Proliferation Index (PI) in malignant lymphomas was assessed using three antibodies. DAKO-EPOS Anti-PCNA/HRP and MIB-1 are suitable for PI evaluation, unlike DAKO-EPOS Anti-Ki-67/HRP.
Area of Science:
- Oncology
- Immunohistochemistry
- Pathology
Context:
- Malignant lymphomas are a group of cancers affecting the lymphatic system.
- Accurate assessment of cell proliferation is crucial for lymphoma diagnosis and prognosis.
- Immunohistochemistry is a key technique for evaluating cell proliferation markers.
Purpose:
- To compare the efficacy of three antibodies in evaluating the Proliferation Index (PI) in malignant lymphomas.
- To determine which antibodies are most reliable for routine PI assessment in lymphoma cases.
Summary:
- The study evaluated the Proliferation Index (PI) in 48 malignant lymphoma cases.
- DAKO-EPOS Anti-PCNA/HRP and MIB-1 (Immunotech) antibodies demonstrated suitability for routine PI evaluation.
- DAKO-EPOS Anti-Ki-67/HRP yielded low PI values and failed to differentiate prognostic groups, indicating its inadequacy.
Impact:
- Identifies reliable antibodies for accurate Proliferation Index assessment in malignant lymphomas.
- Provides guidance for selecting appropriate immunohistochemical markers in lymphoma diagnostics.
- Contributes to improved prognostic stratification and treatment decisions in lymphoma patients.
Abstract:
Proliferation Index (PI) was evaluated in a group of 48 malignant lymphomas. Comparison of 3 antibodies showed that DAKO-EPOS Anti-PCNA/HRP and MIB-1 (Immunotech) suite to routine PI evaluation. Low figures of PI were obtained when using DAKO-EPOS Anti-Ki-67/HRP which did not even discriminate between prognostic groups of malignant lymphomas.